144 related articles for article (PubMed ID: 17311764)
21. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.
Decristoforo C; Faintuch-Linkowski B; Rey A; von Guggenberg E; Rupprich M; Hernandez-Gonzales I; Rodrigo T; Haubner R
Nucl Med Biol; 2006 Nov; 33(8):945-52. PubMed ID: 17127166
[TBL] [Abstract][Full Text] [Related]
22. Near-infrared fluorescent divalent RGD ligand for integrin αvβ₃-targeted optical imaging.
Ye Y; Akers W; Xu B; Bloch S; Odonkor C; Achilefu S
Bioorg Med Chem Lett; 2012 Sep; 22(17):5405-9. PubMed ID: 22871580
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo evaluation of a paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2] that targets integrin alpha v beta 3.
Ryppa C; Mann-Steinberg H; Biniossek ML; Satchi-Fainaro R; Kratz F
Int J Pharm; 2009 Feb; 368(1-2):89-97. PubMed ID: 18992308
[TBL] [Abstract][Full Text] [Related]
24. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in an orthotopic glioblastoma model.
Hsu AR; Hou LC; Veeravagu A; Greve JM; Vogel H; Tse V; Chen X
Mol Imaging Biol; 2006; 8(6):315-23. PubMed ID: 17053862
[TBL] [Abstract][Full Text] [Related]
25. Targeted radionuclide therapy with RAFT-RGD radiolabelled with (90)Y or (177)Lu in a mouse model of αvβ3-expressing tumours.
Bozon-Petitprin A; Bacot S; Gauchez AS; Ahmadi M; Bourre JC; Marti-Batlle D; Perret P; Broisat A; Riou LM; Claron M; Boturyn D; Fagret D; Ghezzi C; Vuillez JP
Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):252-63. PubMed ID: 25164771
[TBL] [Abstract][Full Text] [Related]
26. Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers.
Wu Y; Cai W; Chen X
Mol Imaging Biol; 2006; 8(4):226-36. PubMed ID: 16791749
[TBL] [Abstract][Full Text] [Related]
27. A novel solid lipid nanoparticle formulation for active targeting to tumor α(v) β(3) integrin receptors reveals cyclic RGD as a double-edged sword.
Shuhendler AJ; Prasad P; Leung M; Rauth AM; Dacosta RS; Wu XY
Adv Healthc Mater; 2012 Sep; 1(5):600-8. PubMed ID: 23184795
[TBL] [Abstract][Full Text] [Related]
28. New multifunctional molecular conjugate vector for targeting, imaging, and therapy of tumors.
Garanger E; Boturyn D; Jin Z; Dumy P; Favrot MC; Coll JL
Mol Ther; 2005 Dec; 12(6):1168-75. PubMed ID: 16051524
[TBL] [Abstract][Full Text] [Related]
29. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
30. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo evaluation of doxorubicin conjugates with the divalent peptide E-[c(RGDfK)2] that targets integrin alphavbeta3.
Ryppa C; Mann-Steinberg H; Fichtner I; Weber H; Satchi-Fainaro R; Biniossek ML; Kratz F
Bioconjug Chem; 2008 Jul; 19(7):1414-22. PubMed ID: 18578486
[TBL] [Abstract][Full Text] [Related]
32. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide.
Dijkgraaf I; Liu S; Kruijtzer JA; Soede AC; Oyen WJ; Liskamp RM; Corstens FH; Boerman OC
Nucl Med Biol; 2007 Jan; 34(1):29-35. PubMed ID: 17210459
[TBL] [Abstract][Full Text] [Related]
33. Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy.
Jung KH; Lee KH; Paik JY; Ko BH; Bae JS; Lee BC; Sung HJ; Kim DH; Choe YS; Chi DY
J Nucl Med; 2006 Dec; 47(12):2000-7. PubMed ID: 17138743
[TBL] [Abstract][Full Text] [Related]
34. PET imaging and biodistribution analysis of the effects of succinylated gelatin combined with L-lysine on renal uptake and retention of ⁶⁴Cu-cyclam-RAFT-c(-RGDfK-)₄ in vivo.
Jin ZH; Furukawa T; Sogawa C; Claron M; Aung W; Tsuji AB; Wakizaka H; Zhang MR; Boturyn D; Dumy P; Fujibayashi Y; Saga T
Eur J Pharm Biopharm; 2014 Apr; 86(3):478-86. PubMed ID: 24316338
[TBL] [Abstract][Full Text] [Related]
35. MR/NIRF Dual-Mode Imaging of αvβ3 Integrin-Overexpressing Tumors Using a Lipopeptide-Based Contrast Agent.
Wang Q; Huang L; Zhu X; Zhou Y; Wang J; Su D; Liu L
Mol Pharm; 2021 Dec; 18(12):4543-4552. PubMed ID: 34677979
[TBL] [Abstract][Full Text] [Related]
36. RGD-human serum albumin conjugates as efficient tumor targeting probes.
Chen K; Xie J; Chen X
Mol Imaging; 2009; 8(2):65-73. PubMed ID: 19397852
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo evaluation of a novel 99mTc(CO)3-pyrazolyl conjugate of cyclo-(Arg-Gly-Asp-d-Tyr-Lys).
Alves S; Correia JD; Gano L; Rold TL; Prasanphanich A; Haubner R; Rupprich M; Alberto R; Decristoforo C; Santos I; Smith CJ
Bioconjug Chem; 2007; 18(2):530-7. PubMed ID: 17373771
[TBL] [Abstract][Full Text] [Related]
38. A fluorescent Arg-Gly-Asp (RGD) peptide-naphthalenediimide (NDI) conjugate for imaging integrin α(v)β(3) in vitro.
Hu Z; Arrowsmith RL; Tyson JA; Mirabello V; Ge H; Eggleston IM; Botchway SW; Pantos GD; Pascu SI
Chem Commun (Camb); 2015 Apr; 51(32):6901-4. PubMed ID: 25647279
[TBL] [Abstract][Full Text] [Related]
39. In vivo angiogenesis imaging of solid tumors by alpha(v)beta(3)-targeted, dual-modality micellar nanoprobes.
Kessinger CW; Khemtong C; Togao O; Takahashi M; Sumer BD; Gao J
Exp Biol Med (Maywood); 2010 Aug; 235(8):957-65. PubMed ID: 20660096
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer.
Liu S; Hsieh WY; Jiang Y; Kim YS; Sreerama SG; Chen X; Jia B; Wang F
Bioconjug Chem; 2007; 18(2):438-46. PubMed ID: 17341108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
